- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00353431
Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
BACKGROUND: Prospective randomized trials have shown that near-normoglycemic blood glucose control using insulin infusions achieves a significant reduction in mortality of severely ill patients in intensive care units, of patients with acute myocardial infarction and with stroke. This implies that most severely ill patients with hyperglycemia should be treated with insulin to reach near-normoglycemia. However, this is not common practice today in emergency room admissions outside the intensive care unit, and strategies to achieve near-normoglycemia safely outside the ICU setting with s.c. injections (insulin infusions are too risky outside the ICU) have not been established.
AIM: To evaluate an insulin therapy algorithm using s.c. injections which permits effective and safe glycemic management of emergency room patients with hyperglycemia.
DESIGN: Randomized, controlled trial with an open intervention. Patients presenting with hyperglycemia on admission to the emergency room are randomized 1:1 either to conventional treatment (conventional insulin group) or to intensive treatment (intensive insulin group).
METHODS: 140 patients admitted to the medical emergency rooms of the University Hospital Basel and the Regional Hospital of Solothurn will be included and randomized as described above. All patients with plasma glucose levels exceeding 8.0 mmol/l will be included.
Exclusion criteria include severely immunocompromised patients, patients in shock, patients with terminal illnesses on palliative care, type 1 diabetes with or without ketoacidosis and patients which require intensive care unit (ICU) or cardial care unit (CCU) therapy.
PRIMARY ENDPOINT: Time in the glycaemic target range (5.5-7.0 mmol/l) during the period of observation of 48 hours (expected to be longer in the intensive insulin group)
SECONDARY ENDPOINTS: Time to reach the target range. Frequency of hypoglycaemia (plasma glucose < 3.8 mmol/l). Frequency of severe hypoglycaemia (plasma glucose < 2.5 mmol/l. Frequency of hypokalaemia.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Baselstadt
-
Basel, Baselstadt, Svizzera, 4031
- Division of Endocrinology, Diabetes & Clinical Nutrition, Dept of Internal Medicine,
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- all patients with hyperglycaemia (≥ 8.0 mmol/l) admitted to the medical emergency room.
- patients with presumed hospitalisation in ER or medical ward of more than 48 h duration.
Exclusion Criteria:
- patients in shock (defined as hypotension or shock index > 1 with oliguria, changed mental status and metabolic acidosis)
- patients with a terminal illness on palliative care
- patients with type 1 diabetes
- patients with insulin pump therapy
- patients with need for hospitalisation in the intensive or coronary care unit.
- patients with presumed hospitalisation shorter than 48 hours
- known pregnancy (in women with childbearing potential pregnancy test for exclusion mandatory)
- no informed consent
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: 1
Conventional insulin group: In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician. |
Comparison of a sliding scale with an intensive s.c.
scale
Altri nomi:
|
Sperimentale: 2
Intensive insulin therapy algorithm: The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake. |
Comparison of a sliding scale with an intensive s.c.
scale
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Time in the Glycaemic Target Range (5.5-7.0 mmol/l) During the Period of Observation of 48 Hours
Lasso di tempo: 48 h
|
Hours in which the plasma glucose was between 5.5 and 7.0 mmol/l (expected to be longer in the intensive insulin group)
|
48 h
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Time to Reach the Target Range
Lasso di tempo: 24 h
|
Hours needed to reach 5.5.-7.0 mmol/l (expected to be shorter in the intensive insulin group).
|
24 h
|
Frequency of Hypoglycemia
Lasso di tempo: during observation of 48 hours
|
absolute number of participants with hypoglycemia (plasma glucose < 3.8 mmol/l) (safety endpoint, expected to be similar in the two groups)
|
during observation of 48 hours
|
Frequency of Severe Hypoglycaemia
Lasso di tempo: during observation of 48 hours
|
Number of participants with severe hypoglycaemia (plasma glucose < 2.5 mmol/l) (safety endpoint, expected to be similar in the two groups)
|
during observation of 48 hours
|
Frequency of Hypokalaemia
Lasso di tempo: during observation of 48 hours
|
Number of participants with hypokalaemia (potassium < 3.6 mmol/l, safety endpoint, expected to be similar in the two groups)
|
during observation of 48 hours
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Ulrich Keller, MD, Prof, Division of Endocrinology, Diabetes & Clinical Nutrition, Dept of Internal Medicine
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- EKBB13/06
- ISRCTN55224894 (Identificatore di registro: Current Controlled Trials Database)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Novorapid ®, Novo Nordisk, Denmark
-
Karolinska InstitutetCompletatoDiabete mellito di tipo 2 | Iperglicemia postprandialeSvezia
-
Medical University of WarsawNon ancora reclutamentoDiabete mellito, tipo 1 | Diabete di tipo 1
-
Chen Wei Ren, MDSconosciutoInfarto miocardico acutoCina
-
Woman's Health University Hospital, EgyptCompletatoInfertilità femminile a causa della ridotta riserva ovaricaEgitto
-
Jiangsu HengRui Medicine Co., Ltd.Completato
-
University of FloridaNovo Nordisk A/S; VA Office of Research and DevelopmentCompletato
-
Charite University, Berlin, GermanySconosciutoObesità | Diabete mellito, tipo 1 | Soggetti saniGermania
-
Rigshospitalet, DenmarkSconosciutoAlta statura costituzionale
-
Steno Diabetes Center CopenhagenReclutamento
-
Calibra Medical, Inc.Medpace, Inc.CompletatoDiabete mellito, tipo 2Stati Uniti, Francia, Regno Unito, Germania